Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

Does The Work Of The National Institute For Health And Clinical Excellence (NICE) Have Any Relevance For The United States?

Does The Work Of The National Institute For Health And Clinical Excellence (NICE) Have Any Relevance For The US?

The growing emphasis on evidence-based decision-making in health care, especially regarding health technologies, has generated notable debate and discussion in the U.S. around establishing a more formalized process or system for conducting comparative effectiveness research. In the eyes of many observers, this is quite similar to the health technology assessment programs existing in a number of European countries. The National Institute for Health and Clinical Excellence (NICE) in the U.K. is one the most discussed and debated systems currently in operation, since it represents one of the most sophisticated national attempts to systematically review the value, or relative costs and benefits, of various treatments. The National Pharmaceutical Council commissioned a study of NICE in order to understand its methods of working and to explore its relevance to the United States.

Newsletter Volume

E.V.I.dently June 2015

NPC MessageDriving Health System Value Through Broader Access to DataFrom Fitbits to insurance claims databases, we capture an enormous amount of...
Blog Post

CER Tweets of the Week: CER in the New York Times, AcademyHealth’s Stakeholder Engagement Resources (June 8-12)

This week, comparative effectiveness research (CER) stakeholders shared a @Health_Affairs blog post on how CER can help institutional review boards...
Blog Post

CER Tweets of the Week: CMS at Health Datapalooza, #ASCO15 (June 1-5)

This week, comparative effectiveness research (CER) stakeholders tweeted the Centers for Medicare and Medicaid Services’ (@CMSGov) announcement...
Press Release

NPC Comments on CMS’ Announcement to Allow Broader Access to Publicly Funded Databases

(Washington, DC, June 2, 2015)—The National Pharmaceutical Council (NPC) today commented on the Centers for Medicare and Medicaid Services’ (CMS)...
Press Release

NPC Comments on CMS’ Announcement to Allow Broader Access to Publicly Funded Databases

(Washington, DC, June 2, 2015)—The National Pharmaceutical Council (NPC) today commented on the Centers for Medicare and Medicaid Services’ (CMS)...
Press Release

State Medicaid Directors Share Views on Comparative Effectiveness Research And Its Impact on Policy in National Pharmaceutical Council Survey

(Washington, DC, April 16, 2015)—A new survey conducted on behalf of the National Pharmaceutical Council (NPC) shows that state Medicaid directors...
Press Release

NPC Highlights Stakeholder Views on Comparative Effectiveness Research and the Environment for Health Care Decision-Making

(Washington, DC, March 26, 2015)—A new survey of health care stakeholders reveals continued optimism that comparative effectiveness research (CER)...
Press Release

Fellowship in Health Care Policy Available Through a Partnership of the National Pharmaceutical Council and Milken Institute School of Public Health at The George Washington University

WASHINGTON, DC (September 17, 2014)–The National Pharmaceutical Council (NPC), in conjunction with Milken Institute School of Public Health (Milken...
Commentary and Testimony Page

NPC Comments on PCORI Proposal for Peer Review of Primary Research and Public Release of Research Findings

November 7, 2014Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036Dear Dr....
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
Commentary and Testimony Page

Keeping Our Eye on the CER Ball

Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....
Commentary and Testimony Page

Leveling the Playing Field? Could a Landmark Decision Alter the CER Communications Landscape?

A growing chorus of voices is publicly sharing data on the effectiveness of treatment options, but one viewpoint has long been shut out of key areas...
YouTube Videos

Comparative Effectiveness Research and the Environment for Health Care Decision-Making

During a March 26, 2015 webinar, the National Pharmaceutical Council discussed the results of its annual stakeholder survey on comparative...
YouTube Videos

Incorporating Patient Views Into Health Technology Assessments

David Grainger, senior director, global public policy, Eli Lilly and Company, explains that many health technology assessments are incorporating...
YouTube Videos

Health Technology Assessments and Specialty Medications

David Grainger, senior director, global public policy, Eli Lilly and Company, says that there are often challenges in conducting health technology...
YouTube Videos

Differences in Global Health Technology Assessment

David Grainger, senior director, global public policy, Eli Lilly and Company, describes how health technology assessment (HTA) informs policy and...
Blog Post

CER Tweets of the Week: CER in the New York Times, AcademyHealth’s Stakeholder Engagement Resources (June 8-12)

This week, comparative effectiveness research (CER) stakeholders shared a @Health_Affairs blog post on how CER can help institutional review boards...
Blog Post

CER Tweets of the Week: CMS at Health Datapalooza, #ASCO15 (June 1-5)

This week, comparative effectiveness research (CER) stakeholders tweeted the Centers for Medicare and Medicaid Services’ (@CMSGov) announcement...
Blog Post

CER Tweets of the Week: NPC’s Dr. Dubois in JCER, AcademyHealth’s Data Quality Collaborative Projects (May 25-29)

This week, comparative effectiveness research (CER) stakeholders tweeted the latest column from National Pharmaceutical Council (@npcnow) Chief...
Blog Post

CER Tweets of the Week (May 18-22): CER Stakeholders Tweet Discussions From #ISPORPhila; Generalizing RCT Results to Wider Populations

This week, many comparative effectiveness research (CER) stakeholders attended the International Society for Pharmacoeconomics and Outcomes Research...
  •  
  • 1 of 42
  • >